Actinium Pharmaceuticals develops targeted radiotherapies for cancer using its Antibody Radiation Conjugates platform and alpha-emitting radioisotopes. Company updates commonly focus on ATNM-400, an Actinium-225 antibody radioconjugate studied in solid tumor models including prostate, lung, and breast cancer, and Actimab-A, or lintuzumab-Ac225, an Actinium-225 therapy targeting CD33 in acute myeloid leukemia.
Additional announcements describe radiochemistry work such as chelator-to-antibody ratio optimization, preclinical data presented at oncology and nuclear medicine meetings, and the company's broader radiotherapy platform across solid tumors, hematologic malignancies, and conditioning for cellular therapies.
Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) announced a 1-for-30 reverse stock split effective August 10, 2020. This decision aims to help the company comply with the NYSE American's minimum price requirements. Post-split, there will be approximately 13,585,268 shares outstanding, and no fractional shares will be issued. The reverse split will also adjust the number of shares issuable upon the exercise of outstanding warrants and stock options. Stockholders will receive information regarding their share ownership from the transfer agent.
Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) announced the completion of a public offering, raising approximately $25.0 million by selling 76,923,077 shares at $0.325 per share. Proceeds will fund the ongoing Phase 3 SIERRA trial for its lead candidate, Iomab-B, and support a Biologics License Application to the FDA. Additionally, funds will advance Phase 1 trials for the CD33 program and support general working capital needs. H.C. Wainwright & Co. led the offering with co-placement agents Maxim Group LLC and JonesTrading Institutional Services LLC.
Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) has priced its public offering of 76,923,077 shares at $0.325 per share, expecting gross proceeds of approximately $25 million. The offering is set to close around June 19, 2020. The net proceeds will fund the ongoing Phase 3 SIERRA trial for its product candidate Iomab-B, preparations for a Biologics License Application (BLA), and other developmental initiatives, including Phase 1 trials and general working capital. H.C. Wainwright & Co. is the exclusive placement agent for the offering.
Actinium Pharmaceuticals (NYSE AMERICAN: ATNM) announced a proposed public offering of its common stock, subject to market conditions. The company plans to utilize the net proceeds from the offering to advance its pivotal Phase 3 SIERRA trial for Iomab-B, prepare a Biologics License Application to the FDA, and support commercialization efforts. Additionally, funds will be allocated to Phase 1 trials for its CD33 program, research and development, and general working capital. H.C. Wainwright & Co. is the exclusive placement agent for this offering.